Quince Therapeutics, Inc. Operating Lease, Liability, Noncurrent
Quince Therapeutics, Inc. (QNCX) had Operating Lease, Liability, Noncurrent of $0 as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability, Noncurrent $0.00.
- 2026-03-31: Operating Lease, Liability, Noncurrent $293.00K.
- 2025-12-31: Operating Lease, Liability, Noncurrent $330.00K.
- 2025-09-30: Operating Lease, Liability, Noncurrent $359.00K.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $293.00K 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $330.00K 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $359.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $387.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $383.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $394.00K 10-K · filed 2026-04-10 | |
| 2024-09-30 | $450.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $453.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $394.00K 10-Q · filed 2025-05-13 | $480.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $321.00K 10-K · filed 2025-03-24 | |
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 | |
| 2022-09-30 | $34.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $95.00K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $40.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $420.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $610.00K 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $773.00K 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $171.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $208.00K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $244.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $50.00K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $57.00K 10-Q · filed 2020-05-12 | |
| 2019-03-31 | $475.00K 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |